Zhongjin Irradiation Past Earnings Performance
Past criteria checks 2/6
Zhongjin Irradiation has been growing earnings at an average annual rate of 12.4%, while the Healthcare industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 5.7% per year. Zhongjin Irradiation's return on equity is 12%, and it has net margins of 30.7%.
Key information
12.4%
Earnings growth rate
5.9%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 5.7% |
| Return on equity | 12.0% |
| Net Margin | 30.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Zhongjin Irradiation makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 354 | 109 | 69 | 27 |
| 31 Mar 24 | 348 | 109 | 69 | 26 |
| 31 Dec 23 | 345 | 108 | 68 | 26 |
| 30 Sep 23 | 344 | 110 | 65 | 27 |
| 30 Jun 23 | 343 | 112 | 64 | 26 |
| 31 Mar 23 | 339 | 109 | 63 | 26 |
| 01 Jan 23 | 337 | 108 | 62 | 26 |
| 30 Sep 22 | 332 | 100 | 61 | 24 |
| 30 Jun 22 | 325 | 94 | 62 | 23 |
| 31 Mar 22 | 319 | 93 | 61 | 22 |
| 01 Jan 22 | 309 | 87 | 61 | 21 |
| 30 Sep 21 | 304 | 96 | 47 | 19 |
| 30 Jun 21 | 291 | 90 | 45 | 18 |
| 31 Mar 21 | 282 | 82 | 46 | 18 |
| 31 Dec 20 | 256 | 62 | 45 | 18 |
| 31 Dec 19 | 253 | 58 | 52 | 16 |
| 31 Dec 18 | 244 | 53 | 48 | 15 |
| 31 Dec 17 | 214 | 39 | 49 | 11 |
| 31 Dec 15 | 190 | 30 | 49 | 0 |
| 31 Dec 14 | 156 | 20 | 45 | 0 |
| 31 Dec 13 | 134 | 27 | 37 | 0 |
Quality Earnings: 300962 has high quality earnings.
Growing Profit Margin: 300962's current net profit margins (30.7%) are lower than last year (32.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300962's earnings have grown by 12.4% per year over the past 5 years.
Accelerating Growth: 300962's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300962 had negative earnings growth (-2.9%) over the past year, making it difficult to compare to the Healthcare industry average (-2.5%).
Return on Equity
High ROE: 300962's Return on Equity (12%) is considered low.